drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous anti-CD19 CAR T-cell therapy with CD3ΞΆ/4-1BB costimulation; defined CD4/CD8 composition; used for large B-cell lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lisocabtagene Maraleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-directed chimeric antigen receptor with CD3zeta signaling and 4-1BB costimulation. Upon binding CD19 on malignant B cells, the CAR activates T-cell cytotoxicity, cytokine release, proliferation, and persistence to eliminate CD19-positive tumor cells; product uses a defined CD4/CD8 composition.
drug_name
Lisocabtagene maraleucel (liso-cel)
nct_id_drug_ref
NCT05675982